Table 2 Patient characteristics at the start of MMD (N = 1,082).

From: Integrated multi-month dispensing of antihypertensive and antiretroviral therapy to sustain hypertension and HIV control

Characteristics

Women (n = 677)

Men (n = 405)

P value

Mean Age in yrs., (SD)

49.7 (9.4)

53.0 (9.4)

0.002

Age categories, yrs. (%)

 18–29

2 (0.3)

1 (0.2)

0.001

 30–39

84 (12.4)

25 (6.2)

 

 40–49

250 (36.9)

124 (30.6)

 

 ≥50

341 (50.4)

255 (63.0)

 

BP in mmHg, (SD)

 Mean systolic BP

133.1 (15.8)

137.7 (14.8)

<0.0001

 Mean diastolic BP

86.5 (9.9)

86.7 (10.8)

0.074

% HTN control (Absolute number)

77.1% (521)

67.6% (273)

0.001

BMI in kg/m2, (%)

 Underweight (<19.0)

30 (4.4)

27 (6.7)

0.213

 Normal weight (19.0 to <25.0)

217 (32.1)

213 (52.6)

 

 Overweight (25.0 to <30.0)

237 (35.0)

125 (30.8)

 

 Obese (>30.0)

193 (28.5)

40 (9.9)

 

ART regimen (%)

 TDF-3TC-DTG

486 (71.8)

323 (79.7)

0.005

 TDF-3TC-EFV

85 (12.6)

24 (5.9)

 

 ABC-3TC-EFV

31 (4.6)

13 (3.2)

 

 OTHERS

75 (11.0)

45 (11.2)

 

Duration on ART (%)

 <2 years

10 (1.5)

14 (3.5)

0.114

 3 to <5years

76 (11.2)

42 (10.3)

 

 5 to <10years

256 (37.8)

176 (43.5)

 

 ≥10years

335 (49.5)

173 (42.7)

 

Other comorbidities (%)

 Diabetes mellitus

39 (3.6)

25 (2.3)

0.593

 CKD - eGFR ≤60 ml/min/1.73m2

n = 257

n = 149

 

 CKD Stage 4/5 (0–30)

2 (0.8)

2 (1.3)

0.213

 CKD Stage 3 (30–60)

44 (17.1)

16 (10.7)

 
  1. BMI Body mass index, ART Antiretroviral therapy, eGRF Estimated Glomerular filtration rate, HTN Hypertension, CKD Chronic Kidney Disease, TDF Tenofovir, 3TC Lamivudine, DTG Dolutegravir, ABC Abacavir, EFV Efavirenz.